Full Article
Evidence Summary
What is an Evidence Summary?
Key messages from scientific research that's ready to be acted on
Got It, Hide thisDrug treatments can help people with pain from damaged nerves (neuropathic pain)
Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162-73.
Review question
In adults with painful nerve damage (neuropathic pain), which drugs reduce pain?
Background
Neuropathic pain happens when there are problems with the nerves and they send pain signals to the brain. It is different from pain from injuries or burns, and there are several causes. Neuropathic pain could result from an injury or a disease that affects the nervous system like shingles or diabetes. Several oral and topical (creams or lotions applied to affected areas of skin) drugs can reduce pain.
How the review was done
The researchers did a systematic review, searching for randomized controlled trials published in journals or reported in trial registries up to January 2014.
They found 229 randomized controlled trials.
The key features of the studies were:
- people were of any age and had neuropathic pain caused by a lesion or disease of the nervous system, including postherpetic neuralgia (pain after having shingles) , diabetic and nondiabetic painful polyneuropathy, pain after amputation, neuropathic pain after trauma or surgery, central pain after stroke, spinal cord injury pain, or pain associated with multiple sclerosis;
- drugs were compared with placebo; and
- people were followed for 3 to 24 weeks.
What the researchers found
127 of the trials studied people with diabetic painful polyneuropathy or postherpetic neuralgia.
There was low to high quality evidence on the efficacy of the drugs to reduce pain.
The cause of neuropathic pain did not affect the benefit.
The authors recommended:
- tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, pregabalin, and gabapentin as first-line treatment (strong recommendation);
- lidocaine patches, capsaicin high-concentration patches, and tramadol as second-line treatment (weak recommendation);
- strong opioids and botulinum toxin A as third line treatment (weak recommendation); and
- topical agents and botulinum toxin A for peripheral neuropathic pain (that is, in the legs or arms) only.
Conclusion
Many drug treatments reduce pain in people with neuropathic pain.
Effect of drug treatments versus placebo on pain relief in people with neuropathic pain
| Treatment | Number of trials (number of people) | Rate of pain relief with active treatment* | Rate of pain relief with placebo* | Absolute effect of treatment |
| Tricyclic antidepressants | 15 trials (948 people) | 46% | 18% | About 28 more people out of 100 had less pain |
| Serotonin-noradrenaline reuptake inhibitors | 10 trials (2541 people) | 43% | 28% | About 15 more people out of 100 had less pain |
| Pregabalin | 25 trials (5940 people) | 38% | 24% | About 14 more people out of 100 had less pain |
| Gabapentin or gabapentin extended-release and enacarbil | 14 trials (3503 people) | 35% | 20% | About 15 more people out of 100 had less pain |
| Tramadol | 6 trials (741 people) | 46% | 27% | About 19 more people out of 100 had less pain |
| Strong opioids | 7 trials (838 people) | 49% | 26% | About 23 more people out of 100 had less pain |
| Capsaicin 8% | 6 trials (2073 people) | 36% | 27% | About 9 more people out of 100 had less pain |
| Botulinum toxin A | 4 trials (137 people) | 60% | 6% | About 54 more people out of 100 had less pain |
Related Topics
Glossary
nerve pain
A harmless, inactive, and simulated treatment.
Studies where people are assigned to one of the treatments purely by chance.
A comprehensive evaluation of the available research evidence on a particular topic.
Related Evidence Summaries
-
Physical activity-based interventions using electronic feedback may be ineffective in reducing pain and disability in patients with chronic musculoskeletal pain
Archives of Physical Medicine and Rehabilitation (2017)
-
Self-management education programmes for osteoarthritis
Cochrane Database of Systematic Review (2014)
-
Paracetamol versus placebo for knee and hip osteoarthritis.
Cochrane Database Syst Rev (2019)
